
Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Axsome Therapeutics (AXSM) Analyst Ratings
Bulls say
Axsome Therapeutics is poised for growth with their successful drug Sunosi generating a 34% increase in revenue and upcoming plans for expansion into new indications. The company has a strong cash position and a promising pipeline, including a recently acquired drug for schizophrenia and Tourette syndrome. The author maintains a Buy rating with an increased 12-month price target, but it's important to note potential risks and limitations that could affect the company's future success.
Bears say
Axsome Therapeutics is currently experiencing strong revenue growth, with net product revenue of $153.2M in 1Q26 and a 59% year-over-year increase. However, the company's reliance on a single operating segment and reporting unit, as well as potential challenges with FDA approval for its key pipeline products, may limit its long-term revenue potential. Additionally, with its relatively low payer coverage across all channels, it may struggle to expand its customer base and achieve sustainable growth in the competitive CNS disorders market.
This aggregate rating is based on analysts' research of Axsome Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Axsome Therapeutics (AXSM) Analyst Forecast & Price Prediction
Start investing in Axsome Therapeutics (AXSM)
Order type
Buy in
Order amount
Est. shares
0 shares